Table 1. Mutational Status of Xenografts.
Targeted sequencing on vehicle-treated and progressing combo-treated tumors to examine the mutational status of well-characterized melanoma drivers and suppressors.
| Cell line | BRAF | BRAF zyg | NRAS | HRAS | KRAS | MEK1 | MEK2 | CDK4 | CDKN2A p16INK4a) | PTEN |
|---|---|---|---|---|---|---|---|---|---|---|
| 1205LuTR Vehicle 5 | V600E | het | WT | WT | WT | WT | WT | K22Q | WT | W274X |
| 1205LuTR Vehicle 6 | V600E | het | WT | WT | WT | WT | WT | K22Q | WT | WT |
| CRT 20 | V600E | het | WT | WT | WT | WT | WT | K22Q | E61X, E69X | W274X |
| CRT 21 | V600E | het | WT | WT | WT | WT | WT | K22Q | WT | W274X |
| A375 Vehicle 7 | V600E | hom | WT | WT | WT | WT | WT | WT | E61X, E69X | WT |
| A375 Vehicle 8 | V600E | hom | WT | WT | WT | WT | WT | WT | E61X, E69X | WT |
| CRT 13 | V600E | hom | WT | WT | WT | WT | WT | WT | E61X, E69X | WT |
| CRT 14 | V600E | hom | WT | WT | WT | WT | WT | WT | E61X, E69X | WT |
| CRT 15 | V600E | hom | WT | WT | WT | WT | WT | WT | E69X | WT |